Mkts

Entrada Therapeutics, Inc.

NASDAQ: TRDA
$5.09-0.08 (-1.55%)
As of Nov 13, 9:30 AM ET

Key statistics

Day range
4.915.25
52-week range
4.1116.45
Today
Open5.17
Previous close5.09
Volume791.6K
Valuation
Market cap170.15M
P/E ratio—
EPS (TTM)-3.97
Income & risk
Dividend / yield—
Beta-0.20
Avg volume594.8K
Discussion

TRDA News

Stories mentioning TRDA from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue875.001,2991,6141,95020,55837,39819,57094,694
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development33,05433,95738,36137,87732,07433,40631,25732,035
Sales General & Admin
Total Operating Expenses43,17843,50748,66548,79942,34843,26541,22841,271
Operating Income (Loss)(42,303)(42,208)(47,051)(46,849)(21,790)(5,867)(21,658)53,423
Interest Income
Interest Expense
Other Expense2,6243,1363,5713,9244,4415,1285,7664,366
Pretax Income
Tax Provision38.0092.00654.00178.000.00(1,870)(1,860)2,758
Net Income (Loss)(39,717)(39,164)(44,134)(43,103)(17,349)1,131(14,032)55,031
Earnings Per Share (Basic)(0.95)(0.95)(1.06)(1.04)(0.42)0.03(0.35)1.61
Earnings Per Share (Diluted)(0.95)(0.95)(1.06)(1.04)(0.42)0.03(0.35)1.55
Weighted Average Shares Outstanding (Basic)41,83641,37141,46341,33941,07437,30640,63034,181
Weighted Average Shares Outstanding (Diluted)41,83641,37141,46341,33941,07439,00340,63035,507

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About TRDA

Entrada Therapeutics, Inc. (NASDAQ: TRDA) is a stock listed on the Nasdaq Stock Market under the ticker symbol TRDA. It last traded at $5.09 (Nov 13, 2026, 9:30 AM ET), down 1.6% on the day. That gives Entrada Therapeutics a market capitalisation of $170.2M.

Over the past 52 weeks TRDA has traded between $4.11 and $16.45.

Revenue for the quarter ended Mar 31, 2026 was $875.0K; a net loss of $39.7M. Revenue was down 95.7% from $20.6M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$875.0K-$39.7M-4539.1%
Dec 31, 2025$1.3M-$39.2M-3014.9%
Sep 30, 2025$1.6M-$44.1M-2734.4%
Jun 30, 2025$2.0M-$43.1M-2210.4%

From Entrada Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…